Prevalence and Economic Burden of Respiratory Diseases in Central Asia and Russia: A Systematic Review

Aizhamal Tabyshova, Berik Emilov, Maarten J. Postma, Niels H. Chavannes, Talant Sooronbaev and Job F. M. van Boven
Additional contact information
Aizhamal Tabyshova: Pulmonology Department, National Center of Cardiology and Internal Medicine named after M.M. Mirrakhimov, Bishkek 720040, Kyrgyzstan
Berik Emilov: Pulmonology Department, National Center of Cardiology and Internal Medicine named after M.M. Mirrakhimov, Bishkek 720040, Kyrgyzstan
Maarten J. Postma: Unit of Global Health, Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands
Niels H. Chavannes: Department of Public Health and Primary Care, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
Talant Sooronbaev: Pulmonology Department, National Center of Cardiology and Internal Medicine named after M.M. Mirrakhimov, Bishkek 720040, Kyrgyzstan
Job F. M. van Boven: Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands

IJERPH, 2020, vol. 17, issue 20, 1-13

Abstract: Prevalence data of respiratory diseases (RDs) in Central Asia (CA) and Russia are contrasting. To inform future research needs and assist government and clinical policy on RDs, an up-to-date overview is required. We aimed to review the prevalence and economic burden of RDs in CA and Russia. PubMed and EMBASE databases were searched for studies that reported prevalence and/or economic burden of RDs (asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, interstitial lung diseases (ILD), lung cancer, pulmonary hypertension, and tuberculosis (TB)) in CA (Kyrgyzstan, Uzbekistan, Tajikistan, Kazakhstan, and Turkmenistan) and Russia. A total of 25 articles (RD prevalence: 18; economics: 7) were included. The majority ( n = 12), mostly from Russia, reported on TB. TB prevalence declined over the last 20 years, to less than 100 per 100,000 across Russia and CA, yet in those, multidrug-resistant tuberculosis (MDR-TB) was alarming high (newly treated: 19–26%, previously treated: 60–70%). COPD, asthma (2–15%) and ILD (0.006%) prevalence was only reported for Russia and Kazakhstan. No studies on cystic fibrosis, lung cancer and pulmonary hypertension were found. TB costs varied between US$400 (Tajikistan) and US$900 (Russia) for drug-susceptible TB to ≥US$10,000 for MDR-TB (Russia). Non-TB data were scarce and inconsistent. Especially in CA, more research into the prevalence and burden of RDs is needed.

Keywords: prevalence; economic burden; chronic respiratory diseases; Central Asia; Russia (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/20/7483/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/20/7483/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:20:p:7483-:d:428175

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().